GD2-Ganglioside - Amerigo Scientific

- Overview
  - GD2 (shown as sodium salt) has a core trisaccharide structure (GalNAcβ1,4Galβ1,4Glc) with its two sialic acids linked α2,3/α2,8 to the inner galactose residue and ceramide linked β to position 1 on the reducing terminal glucose residue (Ledeen, 2009). GD2 ganglioside is expressed at a low concentration in the central nervous system, nerves, skin melanocytes and stem cells in healthy adults. On the other hand, GD2 is overexpressed in a number of tumors, including: neuroblastoma, melanoma, small cell lung carcinoma and brain tumors. Recently, it has been found in low concentrations on breast cancer stem cells (CSC) that possess: self-renewal properties (division without disrupting the undifferentiated state), and tumor-initiating capabilities. It has been suggested that GD2 ganglioside may be developed as an effective target antigen for CSC immunotherapy (Fleurence, 2017).
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Ganglioside Oligosaccharides and Gangliosides
    
    Alternative Name
    
    Disialoganglioside-GD2
    
    CAS Number
    
    65988-71-8
    
    Molecular Formula
    
    C78H138N4O34·xNa
    
    Molecular Weight
    
    1,675.94 g/mol
    
    MDL Number
    
    MFCD01093866
    
    Note
    
    There is no hazardous surcharge associated with this product.
    There is no special packaging charge associated with this product.
    
    * For research use only. Not for human or veterinary use
- Reference
  - Ledeen et al (2009) Neurobiology Meets Glycosciences, In: The Sugar Code (Ed: Gabius H. J) pp 495-516, Wiley-VCH, Weinheim.
    Fleurence et al (2017) Review Article, Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy, Journal of Immunology Research Volume 2017, 16 pages.